Bioinformatics and variability in drug response: A protein structural perspective

Journal of the Royal Society Interface

Volumn 9, Issue 72, 2012, Pages 1409-1437

  Lahti, Jennifer L ^a   Tang, Grace W ^a   Capriotti, Emidio ^a,b   Liu, Tianyun ^c   Altman, Russ B ^a,c  

^a Stanford University   (United States)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Bioinformatics; Drug response; Pharmacogenetics; Protein structure

Indexed keywords

BIOINFORMATICS; DRUG INTERACTIONS;

ADVERSE EFFECT; CLINICAL PRACTICES; CLINICAL TRIAL; DRUG RESPONSE; DRUG TARGETS; GENETIC DIFFERENCES; PARADIGM SHIFTS; PATIENT POPULATION; PERSONALIZED MEDICINES; PHARMACOGENETICS; PROTEIN STRUCTURES; PROTEIN TARGETS; STRUCTURAL CHARACTERISTICS; STRUCTURAL GENOMICS; THERAPEUTIC COMPOUNDS; THREE-DIMENSIONAL STRUCTURE;

PROTEINS;

ANDROGEN RECEPTOR; PROTEIN P53;

BIOINFORMATICS; DATA BASE; DRUG ACTIVITY; DRUG BINDING; DRUG BINDING SITE; DRUG INTERACTION; DRUG RESPONSE; DRUG TARGETING; GENETIC DIFFERENCE; GENETIC VARIABILITY; HUMAN; MATHEMATICAL COMPUTING; MISSENSE MUTATION; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; MUTATION; PHARMACOGENETICS; PHYSICAL CHEMISTRY; PROTEIN CONFORMATION; PROTEIN DRUG INTERACTION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SIMULATION; STRUCTURAL GENOMICS; THERMOSTABILITY;

EID: 84863598108     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2011.0843     Document Type: Review

References (332)

1. Rask-Andersen, M., Almen, M. S. & Schioth, H. B. 2011 Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590. (doi:10.1038/nrd3478)
2. Pammolli, F., Magazzini, L. & Riccaboni, M. 2011 The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428-438. (doi:10.1038/nrd3405)
3. Watkins, P. B. 2011 Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther. 89, 788-790. (doi:10.1038/clpt.2011.63)
4. Lesko, L. J. & Woodcock, J. 2004 Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat. Rev. Drug Discov. 3, 763-769. (doi:10.1038/nrd1499)
5. Wilkinson, G. R. 2005 Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221. (doi:10.1056/NEJMra032424)
6. Sadee, W. & Dai, Z. 2005 Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14 Spec No. 2, R207-R214. (doi:10.1093/hmg/ddi261)
7. Wilke, R. A. & Dolan, M. E. 2011 Genetics and variable drug response. J. Am. Med. Assoc. 306, 306-307. (doi:10.1001/jama.2011.998)
8. Eichler, H. G. et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 10, 495-506. (doi:10.1038/nrd3501)
9. Brunton, L. L., Chabner, B. A. & Knollmann, B. C. 2011 Pharmacodynamics: molecular mechanisms of drug action. In Goodman and Gilman's the pharmacological basis of therapeutics (ed. L. L. Brunton), 12th edn. New York, NY: The McGraw-Hill Companies, Inc.
10. Carlquist, J. F. & Anderson, J. L. 2011 Pharmacogenetic mechanisms underlying unanticipated drug responses. Discov. Med. 11, 469-478.
11. Roses, A. D. 2008 Pharmacogenetics in drug discovery and development: a translational perspective. Nat. Rev. Drug Discov. 7, 807-817. (doi:10.1038/nrd2593)
12. Daly, A. K. 2010 Pharmacogenetics and human genetic polymorphisms. Biochem. J. 429, 435-449. (doi:10.1042/BJ20100522)
13. Fernald, G. H., Capriotti, E., Daneshjou, R., Karczewski, K. J. & Altman, R. B. 2011 Bioinformatics challenges for personalized medicine. Bioinformatics 27, 1741-1748. (doi:10.1093/bioinformatics/btr295)
14. Teng, S., Michonova-Alexova, E. & Alexov, E. 2008 Approaches and resources for prediction of the effects of non-synonymous single nucleotide polymorphism on protein function and interactions. Curr. Pharm. Biotechnol. 9, 123-133. (doi:10.2174/138920108783955164)
15. Capriotti, E. & Altman, R. B. 2011 Improving the prediction of disease-related variants using protein three-dimensional structure. BMC Bioinformatics 12 (Suppl. 4), S3. (doi:10.1186/1471-2105-12-S4-S3)
16. Weigelt, J. 2010 Structural genomics-impact on biomedicine and drug discovery. Exp. Cell Res. 316, 1332-1338. (doi:10.1016/j.yexcr.2010.02.041)
17. National Drug Code Directory [database on the Internet]. 2011 U.S. Food and Drug Administration. [cited August 1, 2011]. Available from: http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm.
18. Swinney, D. C. & Anthony, J. 2011 How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519. (doi:10.1038/nrd3480)
19. Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L. & Hipskind, P. A. 2004 Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 47, 224-232. (doi:10.1021/jm030267j)
20. Bauer, R.A.,Wurst, J. M.&Tan, D. S. 2010 Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective. Curr. Opin. Chem. Biol. 14, 308-314. (doi:10.1016/j.cbpa.2010.02. 001)
21. Benjamin, B., Barman, T. K., Chaira, T. & Paliwal, J. K. 2010 Integration of physicochemical and pharmacokinetic parameters in lead optimization: a physiological pharmacokinetic model based approach. Curr. Drug Discov. Technol. 7, 143-153.
22. Gleeson, M. P., Hersey, A., Montanari, D.& Overington, J. 2011 Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10, 197-208. (doi:10.1038/nrd3367)
23. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. 1997 Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25. (doi:10.1016/S0169-409X(96)00423-1)
24. Oprea, T. I. 2000 Property distribution of drug-related chemical databases. J. Comput. Aided Mol. Des. 14, 251-264. (doi:10.1023/A:1008130001697)
25. Hann, M. M., Leach, A. R. & Harper, G. 2001 Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856-864. (doi:10.1021/ci000403i)
26. Mestres, J.,Gregori-Puigjane, E., Valverde, S. & Sole, R. V. 2009 The topology of drug-target interaction networks, implicit dependence on drug properties and target families. Mol. Biosyst. 5, 1051-1057. (doi:10.1039/ b905821b)
27. Vieth, M. & Sutherland, J. J. 2006 Dependence of molecular properties on proteomic family for marketed oral drugs. J. Med. Chem. 49, 3451-3453. (doi:10.1021/jm0603825)
28. Bakheet, T. M. & Doig, A. J. 2009 Properties and identification of human protein drug targets. Bioinformatics. 25, 451-457. (doi:10.1093/ bioinformatics/btp002)
29. Hopkins, A. L. & Groom, C. R. 2002 The druggable genome. Nat. Rev. Drug Discov. 1, 727-730. (doi:10.1038/nrd892)
30. Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C. & Huang, E. S. 2007 Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 25, 71-75. (doi:10.1038/nbt1273)
31. Najmanovich, R., Kurbatova, N. & Thornton, J. 2008 Detection of 3D atomic similarities and their use in the discrimination of small molecule protein-binding sites. Bioinformatics 24, i105-i111. (doi:10.1093/ bioinformatics/btn263)
32. Halgren, T. A. 2009 Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model 49, 377-389. (doi:10.1021/ci800324m)
33. Nayal, M. & Honig, B. 2006 On the nature of cavities on protein surfaces: application to the identification of drug-binding sites. Proteins 63, 892-906. (doi:10.1002/prot.20897)
34. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N. & Bourne, P. E. 2000 The Protein Data Bank. Nucleic Acids Res. 28, 235-242. (doi:10.1093/nar/28.1.235)
35. Murzin, A. G., Brenner, S. E., Hubbard, T. & Chothia, C. 1995 SCOP: a structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 247, 536-540. (doi:10.1016/S0022- 2836(05)80134-2)
36. Li, B., Turuvekere, S., Agrawal, M., La, D., Ramani, K. & Kihara, D. 2008 Characterization of local geometry of protein surfaces with the visibility criterion. Proteins 71, 670-683. (doi:10.1002/prot.21732)
37. Fuller, J. C., Burgoyne, N. J. & Jackson, R. M. 2009 Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today 14, 155-161. (doi:10.1016/j.drudis.2008.10.009)
38. Volkamer, A., Griewel, A., Grombacher, T. & Rarey, M. 2010 Analyzing the topology of active sites, on the prediction of pockets and subpockets. J. Chem. Inf. Model 50, 2041-2052. (doi:10.1021/ci100241y)
39. Smith, R. D., Hu, L., Falkner, J. A., Benson, M. L., Nerothin, J. P. & Carlson, H. A. 2006 Exploring protein-ligand recognition with binding MOAD. J. Mol. Graph Model 24, 414-425. (doi:10.1016/j.jmgm.2005.08.002)
40. Hajduk, P. J., Huth, J. R. & Fesik, S.W. 2005 Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48, 2518-2525. (doi:10.1021/jm049131r)
41. Schmidtke, P. & Barril, X. 2010 Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J. Med. Chem. 53, 5858-5867. (doi:10.1021/jm100574m)
42. Wass, M. N., David, A. & Sternberg, M. J. 2011 Challenges for the prediction of macromolecular interactions. Curr. Opin. Struct. Biol. 21, 382-390. (doi:10.1016/j.sbi.2011.03.013)
43. Wells, J. A. & McClendon, C. L. 2007 Reaching for highhanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009. (doi:10.1038/nature06526)
44. Park, C. M. et al. 2008 Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 51, 6902-6915. (doi:10.1021/jm800669s)
45. 2004 Finishing the euchromatic sequence of the human genome. Nature 431, 931-945. (doi:10.1038/nature03001)
46. Landry, Y. & Gies, J. P. 2008 Drugs and their molecular targets: an updated overview. Fundam. Clin. Pharmacol. 22, 1-18. (doi:10.1111/j.1472-8206. 2007.00548.x)
47. Plewczynski, D. & Rychlewski, L. 2009 Meta-basic estimates the size of druggable human genome. J. Mol. Model 15, 695-699. (doi:10.1007/s00894-008- 0353-5)
48. Knox, C. et al. 2011 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041. (doi:10.1093/nar/gkq1126)
49. Southan, C., Boppana, K., Jagarlapudi, S. A. & Muresan, S. 2011 Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: ranking 1654 human protein targets by assayed compounds and molecular scaffolds. J. Cheminform. 3, 14. (doi:10.1186/1758-2946-3-14)
50. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. 2006 How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996. (doi:10.1038/nrd2199)
51. Spyrakis,F.,BidonChanal,A., Barril, X.&Luque,F. J. 2011 Protein flexibility and ligand recognition: challenges for molecular modeling. Curr. Top. Med. Chem. 11, 192-210.
52. Okazaki, K. & Takada, S. 2008 Dynamic energy landscape view of coupled binding and protein conformational change: induced-fit versus population-shift mechanisms. Proc. Natl Acad. Sci. USA 105, 11182-11187. (doi:10.1073/pnas.0802524105)
53. Boehr, D. D., Nussinov, R. &Wright, P. E. 2009 The role of dynamic conformational ensembles in biomolecular recognition. Nat. Chem. Biol. 5, 789-796. (doi:10.1038/nchembio.232)
54. Hansen,G.,Gielen-Haertwig,H.,Reinemer, P., Schomburg, D., Harrenga, A. & Niefind, K. 2011 Unexpected active-site flexibility in the structure of human neutrophil elastase in complex with a new dihydropyrimidone inhibitor. J. Mol. Biol. 409, 681-691. (doi:10.1016/j.jmb.2011.04.047)
55. Aleksandrov, A. & Simonson, T. 2010 Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J. Biol. Chem. 285, 13 807-13 815. (doi:10.1074/jbc.M110.109660)
56. Long, D. & Bruschweiler, R. 2011 In silico elucidation of the recognition dynamics of ubiquitin. PLoS Comput. Biol. 7, e1002035. (doi:10.1371/journal.pcbi.1002035)
57. Silva, D.A., Bowman,G. R., Sosa-Peinado,A.&Huang, X. 2011 A role for both conformational selection and induced fit in ligand binding by the LAO protein. PLoS Comput. Biol. 7, e1002054. (doi:10.1371/journal.pcbi.1002054)
58. Chayen, N. E. & Saridakis, E. 2008 Protein crystallization: from purified protein to diffraction-quality crystal. Nat. Methods 5, 147-153. (doi:10.1038/nmeth.f.203)
59. Tang, G. W. & Altman, R. B. 2011 Remote thioredoxin recognition using evolutionary conservation and structural dynamics. Structure 19, 461-470. (doi:10.1016/j.str.2011.02.007)
60. Glazer, D. S., Radmer, R. J. & Altman, R. B. 2009 Improving structure-based function prediction using molecular dynamics. Structure 17, 919-929. (doi:10.1016/j.str.2009.05.010)
61. Kortagere, S., Krasowski, M. D. & Ekins, S. 2009 The importance of discerning shape in molecular pharmacology. Trends Pharmacol. Sci. 30, 138-147. (doi:10.1016/j.tips.2008.12.001)
62. Filippakopoulos, P. et al. 2010 Selective inhibition of BET bromodomains. Nature 468, 1067-1073. (doi:10.1038/nature09504)
63. Ceccarelli, D. F. et al. 2011 An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell 145, 1075-1087. (doi:10.1016/j.cell.2011.05. 039)
64. Ballester, P. J., Westwood, I., Laurieri, N., Sim, E. & Richards, W. G. 2010 Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases. J. R. Soc. Interface 7, 335-342. (doi:10.1098/rsif.2009.0170)
65. Ebalunode, J. O. & Zheng, W. 2010 Molecular shape technologies in drug discovery: methods and applications. Curr. Top. Med. Chem. 10, 669-679. (doi:10.2174/156802610791111489)
66. Kukic, P. & Nielsen, J. E. 2010 Electrostatics in proteins and protein-ligand complexes. Future Med. Chem. 2, 647-666. (doi:10.4155/fmc.10.6)
67. Wang, H., Blais, J., Ron, D. & Cardozo, T. 2010 Structural determinants of PERK inhibitor potency and selectivity. Chem. Biol. Drug Des. 76, 480-95. (doi:10.1111/j.1747-0285.2010.01048.x)
68. Snyder, P. W. et al. 2011 Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase. Proc. Natl Acad. Sci. USA 108, 17 889-17 894. (doi:10.1073/pnas.1114107108)
69. Arunan, E. et al. 2011 Definition of the hydrogen bond (IUPAC Recommendations 2011). Pure Appl. Chem. 83, 1637-1641. (doi:10.1351/PAC-REC-10- 01-02)
70. Urwyler, S. 2011 Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol. Rev. 63, 59-126. (doi:10.1124/pr.109.002501)
71. Schindler, T., Bornmann,W., Pellicena, P., Miller,W. T., Clarkson, B. & Kuriyan, J. 2000 Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942. (doi:10.1126/science.289.5486.1938)
72. Karaman, M. W. et al. 2008 A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132. (doi:10.1038/nbt1358)
73. Branca, M. A. 2005 Multi-kinase inhibitors create buzz at ASCO. Nat. Biotechnol. 23, 639. (doi:10.1038/nbt0605-639)
74. Sessel, S. & Fernandez, A. 2011 Selectivity filters to edit out deleterious side effects in kinase inhibitors. Curr. Top. Med. Chem. 11, 788-799. (doi:10.2174/156802611795165089)
75. Ma, X. H., Shi, Z., Tan, C., Jiang, Y., Go, M. L., Low, B. C. & Chen, Y. Z. 2010 In-silico approaches to multitarget drug discovery: computer aided multi-target drug design, multi-target virtual screening. Pharm. Res. 27, 739-749. (doi:10.1007/s11095-010-0065-2)
76. Schwartz, T. W. & Holst, B. 2007 Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol. Sci. 28, 366-373. (doi:10.1016/j.tips.2007.06.008)
77. Eglen, R. & Reisine, T. 2011 Drug discovery and the human kinome: recent trends. Pharmacol. Ther. 130, 144-156. (doi:10.1016/j.pharmthera.2011.01. 007)
78. Gjoni, T. & Urwyler, S. 2008 Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization. Neuropharmacology 55, 1293-1299. (doi:10.1016/j.neuropharm. 2008.08.008)
79. Bowery, N. G. 2006 Allosteric receptor modulation in drug targeting. New York, NY: Taylor and Francis Group.
80. Sadowsky, J. D., Burlingame, M. A., Wolan, D. W., McClendon, C. L., Jacobson, M. P. & Wells, J. A. 2011 Turning a protein kinase on or off from a single allosteric site via disulfide trapping. Proc. Natl Acad. Sci. USA 108, 6056-6061. (doi:10.1073/pnas.1102376108)
81. Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Edwards, P. C., Henderson, R., Leslie, A. G., Tate, C. G. & Schertler, G. F. 2008 Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454, 486-491. (doi:10.1038/nature07101)
82. Lewis, J. A., Lebois, E. P. & Lindsley, C. W. 2008 Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr. Opin. Chem. Biol. 12, 269-280. (doi:10.1016/j.cbpa.2008.02.014)
83. Ashley, E. A. et al. 2010 Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535. (doi:10.1016/S0140-6736(10)60452-7)
84. Dewey, F. E. et al. 2011 Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet. 7, e1002280. (doi:10.1371/journal.pgen.1002280)
85. 2010 A map of human genome variation from populationscale sequencing. Nature 467, 1061-1073. (doi:10.1038/nature09534)
86. Mendell, J. T. & Dietz, H. C. 2001 When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 107, 411-414. (doi:10.1016/S0092-8674(01)00583-9)
87. Stenson, P. D., Mort, M., Ball, E. V., Howells, K., Phillips, A. D., Thomas, N. S. & Cooper, D. N. 2009 The Human Gene Mutation Database: 2008 update. Genome Med. 1, 13. (doi:10.1186/gm13)
88. Capriotti, E., Nehrt, N. L., Kann, M. G. & Bromberg, Y. 2012 Bioinformatics for personal genome interpretation. Brief Bioinform. (doi:10.1093/bib/bbr070)
89. Calabrese, R., Capriotti, E., Fariselli, P., Martelli, P. L. & Casadio, R. 2009 Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum. Mutat. 30, 1237-44. (doi:10.1002/humu.21047)
90. Capriotti, E. & Altman, R. B. 2011 A new diseasespecific machine learning approach for the prediction of cancer-causing missense variants. Genomics 98, 310-317. (doi:10.1016/j.ygeno.2011.06.010)
91. Capriotti, E., Arbiza, L., Casadio, R., Dopazo, J., Dopazo, H. & Marti-Renom, M. A. 2008 Use of estimated evolutionary strength at the codon level improves the prediction of disease-related protein mutations in humans. Hum. Mutat. 29, 198-204. (doi:10.1002/humu.20628)
92. Capriotti, E., Calabrese, R. & Casadio, R. 2006 Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics 22, 2729-2734. (doi:10.1093/bioinformatics/btl423)
93. Li, B., Krishnan, V. G., Mort, M. E., Xin, F., Kamati, K. K., Cooper, D. N., Mooney, S. D. & Radivojac, P. 2009 Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics 25, 2744-2750. (doi:10.1093/bioinformatics/btp528)
94. Ng, P. C. & Henikoff, S. 2003 SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814. (doi:10.1093/nar/gkg509)
95. Karchin, R., Diekhans, M.,Kelly, L., Thomas, D. J., Pieper, U., Eswar, N., Haussler, D. & Sali, A. 2005 LS-SNP: largescale annotation of coding non-synonymous SNPs based on multiple information sources. Bioinformatics 21, 2814-2820. (doi:10.1093/bioinformatics/bti442)
96. Ramensky, V., Bork, P. & Sunyaev, S. 2002 Human nonsynonymous SNPs: server and survey. Nucleic Acids Res. 30, 3894-900. (doi:10.1093/nar/gkf493)
97. Yue, P. & Moult, J. 2006 Identification and analysis of deleterious human SNPs. J. Mol. Biol. 356, 1263-1274. (doi:10.1016/j.jmb.2005.12.025)
98. Dehouck, Y., Grosfils, A., Folch, B., Gilis, D., Bogaerts, P. & Rooman, M. 2009 Fast and accurate predictions of protein stability changes upon mutations using statistical potentials and neural networks: PoPMuSiC-2.0. Bioinformatics 25, 2537-2543. (doi:10.1093/bioinfor matics/btp445)
99. Capriotti, E., Fariselli, P., Rossi, I. & Casadio, R. 2008 A three-state prediction of single point mutations on protein stability changes. BMC Bioinformatics 9 (Suppl. 2), S6. (doi:10.1186/1471-2105-9-S2-S6)
100. Schymkowitz, J., Borg, J., Stricher, F., Nys, R., Rousseau, F. & Serrano, L. 2005 The FoldX web server: an online force field. Nucleic Acids Res. 1; 33. (Web Server issue; W382-W388.)
101. Capriotti, E., Fariselli, P. & Casadio, R. 2005 I Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res. 1, 33. (Web Server issue; W306-W310.)
102. Zhang, J., Yang, P. L. & Gray, N. S. 2009 Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39. (doi:10.1038/nrc2559)
103. Fei, F., Stoddart, S., Groffen, J. & Heisterkamp, N. 2010 Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias. Mol. Cancer Ther. 9, 1318-1327. (doi:10.1158/1535-7163.MCT-10-0069)
104. Zhou, T. et al. 2007 Crystal structure of the T315I mutant of AbI kinase. Chem. Biol. Drug Des. 70, 171-181. (doi:10.1111/j.1747-0285.2007.00556.x)
105. Cowan-Jacob, S. W. et al. 2007 Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr. D Biol. Crystallogr. 63, 80-93. (Pubitemid 46141483)
106. Chan,W.W. et al. 2011 Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 19, 556-568. (doi:10.1016/j.ccr.2011.03.003)
107. Zhou, T. et al. 2011 Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem. Biol. Drug Des. 77, 1-11. (doi:10.1111/j.1747-0285.2010.01054.x)
108. Cheetham, G. M., Charlton, P. A., Golec, J. M. & Pollard, J. R. 2007 Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 251, 323-329. (doi:10.1016/j.canlet.2006.12.004)
109. Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H. & Mitsudomi, T. 2006 Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12, 5764-5769. (doi:10.1158/1078-0432.CCR-06-0714)
110. Balak, M. N. et al. 2006 Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12, 6494-6501. (doi:10.1158/1078-0432.CCR-06-1570)
111. Kobayashi, S. et al. 2005 EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792. (doi:10.1056/ NEJMoa044238)
112. Yun, C. H., Mengwasser, K. E., Toms, A. V.,Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M. & Eck, M. J. 2008 The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 2070-2075. (doi:10.1073/pnas.0709662105)
113. Zhou, W. et al. 2009 Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074. (doi:10.1038/nature08622)
114. van de Wijngaart, D. J., Molier, M., Lusher, S. J., Hersmus, R., Jenster, G., Trapman, J. & Dubbink, M. J. 2010 Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J. Biol. Chem. 285, 5097-5105. (doi:10.1074/jbc.M109.039958)
115. Tran, C. et al. 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790. (doi:10.1126/science.1168175)
116. Sack, J. S. et al. 2001 Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl Acad. Sci. USA 98, 4904-4909. (doi:10.1073/pnas.081565498)
117. Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E. & Dalton, J. T. 2005 Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl Acad. Sci. USA 102, 6201-6206. (doi:10.1073/pnas.0500381102)
118. Bohl, C. E., Miller, D. D., Chen, J., Bell, C. E. & Dalton, J. T. 2005 Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J. Biol. Chem. 280, 37 747-37 754. (doi:10.1074/jbc.M507464200)
119. Bohl, C. E., Wu, Z., Miller, D. D., Bell, C. E. & Dalton, J. T. 2007 Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J. Biol. Chem. 282, 13 648-13 655. (doi:10.1074/jbc.M611711200)
120. Ho, B. K. & Gruswitz, F. 2008 HOLLOW, generating accurate representations of channel and interior surfaces in molecular structures. BMC Struct. Biol. 8, 49. (doi:10.1186/1472-6807-8-49)
121. Pereira de Jesus-Tran, K., Cote, P. L., Cantin, L., Blanchet, J., Labrie, F. & Breton, R. 2006 Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. 15, 987-999. (doi:10.1110/ps.051905906)
122. Scher, H. I. et al. 2010 Antitumour activity of MDV3100 in castration-resistant prostate cancer, a phase 1-2 study. Lancet 375, 1437-1446. (doi:10.1016/S0140-6736(10)60172-9)
123. Corless, C. L., Fletcher, J. A. & Heinrich, M. C. 2004 Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 22, 3813-3825. (doi:10.1200/JCO.2004.05.140)
124. Verweij, J. et al. 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364, 1127-1134. (doi:10.1016/S0140-6736(04)17098-0)
125. Heinrich, M. C. et al. 2008 Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 26, 5352-5359. (doi:10.1200/JCO.2007.15.7461)
126. Mol, C. D. et al. 2003 Structure of a c-Kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278, 31 461-31 464. (doi:10.1074/jbc.C300186200)
127. Mol, C. D. et al. 2004 Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279, 31 655-31 663. (doi:10.1074/jbc.M403319200)
128. Gajiwala, K. S. et al. 2009 KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl Acad. Sci. USA 106, 1542-1547. (doi:10.1073/pnas. 0812413106)
129. Pan, B. S. et al. 2010 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 70, 1524-1533. (doi:10.1158/0008-5472.CAN-09-2541)
130. Tsai, J. et al. 2008 Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046. (doi:10.1073/pnas.0711741105)
131. Lane, D. P., Cheok, C. F. & Lain, S. 2010 p53-based cancer therapy. Cold Spring Harb. Perspect. Biol. 2, a001222. (doi:10.1101/cshperspect.a001222)
132. Wiman, K. G. 2010 Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29, 4245-4252. (doi:10.1038/onc.2010.188)
133. Boeckler, F. M., Joerger,A. C., Jaggi,G., Rutherford, T. J., Veprintsev, D. B.& Fersht, A. R. 2008 Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl Acad. Sci. USA 105, 10360-10365. (doi:10.1073/pnas.0805326105)
134. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J. & Pavletich, N. P. 1996 Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953. (doi:10.1126/science.274.5289.948)
135. Secchiero, P., Bosco, R., Celeghini, C. & Zauli, G. 2011 Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des. 17, 569-577. (doi:10.2174/138161211795222586)
136. Azmi, A. S., Philip, P. A., Almhanna, K., Beck, F. W., Sarkar, F. H. & Mohammad, R. M. 2010 MDM2 inhibitors for pancreatic cancer therapy. Mini Rev. Med. Chem. 10, 518-526. (doi:10.2174/138955710791384054)
137. Pishas, K. I., Al-Ejeh, F., Zinonos, I., Kumar, R., Evdokiou, A., Brown, M. P., Callan, D. F. & Neilsen, P. M. 2011 Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin. Cancer Res. 17, 494-504. (doi:10.1158/1078-0432.CCR-10-1587)
138. Azmi, A. S. et al. 2010 Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr. Cancer Drug Targets 10, 319-331. (doi:10.2174/156800910791190229)
139. Joerger, A. C., Ang, H. C. & Fersht, A. R. 2006 Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl Acad. Sci. USA 103, 15 056-15 061. (doi:10.1073/pnas.0607286103)
140. Saddler, C. et al. 2008 Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111, 1584-1593. (doi:10.1182/blood-2007-09- 112698)
141. Joerger, A. C., Allen, M. D. & Fersht, A. R. 2004 Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J. Biol. Chem. 279, 1291-1296. (doi:10.1074/jbc.M309732200)
142. Bullock, A. N., Henckel, J. & Fersht, A. R. 2000 Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245-1256. (doi:10.1038/sj.onc.1203434)
143. Basse, N., Kaar, J. L., Settanni, G., Joerger, A. C., Rutherford, T. J. & Fersht, A. R. 2010 Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem. Biol. 17, 46-56. (doi:10.1016/j.chembiol.2009.12.011)
144. Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak Vinkovic, D. & Jhoti, H. 2003 Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424, 464-468. (doi:10.1038/nature01862)
145. Thorn, C. F., Aklillu, E., Klein, T. E. & Altman, R. B. 2011 PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet. Genom. 22, 73-77. (doi:10.1097/FPC.0b013e32834c6efd)
146. Thorn, C. F., Lamba, J. K., Lamba, V., Klein, T. E. & Altman, R. B. 2010 PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet. Genom. 20, 520-523. (doi:10.1097/FPC.0b013e32833947c2)
147. Van Booven, D., Marsh, S., McLeod, H., Carrillo, M. W., Sangkuhl, K., Klein, T. E. & Altman, R. B. 2010 Cytochrome P450 2C9-CYP2C9. Pharmacogenet. Genom. 20, 277-281.
148. Owen, R. P., Sangkuhl, K., Klein, T. E. & Altman, R. B. 2009 Cytochrome P450 2D6. Pharmacogenet. Genom. 19, 559-562. (doi:10.1097/FPC. 0b013e32832e0e97)
149. Berlin,D. S., Sangkuhl,K., Klein,T. E.&Altman, R. B. 2011 PharmGKB summary: cytochrome P450, family 2, subfamily, J., polypeptide 2: CYP2J2. Pharmacogenet. Genom. 21, 308-311. (doi:10.1097/FPC.0b013e328 33d1011)
150. Schuetz, E. G. et al. 2004 PharmGKB update. II. CYP3A5, cytochrome P450, family 3, subfamily, A., polypeptide 5. Pharmacol. Rev. 56, 159. (doi:10.1124/pr.56.2.1)
151. Hendrychova, T., Anzenbacherova, E., Hudecek, J., Skopalik, J., Lange, R., Hildebrandt, P., Otyepka, M. & Anzenbacher, P. 2011 Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations. Biochim. Biophys. Acta 1814, 58-68.
152. Skopalik, J., Anzenbacher, P. & Otyepka, M. 2008 Flexibility of human cytochromes P450: molecular dynamics reveals differences between CYPs 3A4, 2C9, and 2A6, which correlate with their substrate preferences. J. Phys. Chem. B 112, 8165-8173. (doi:10.1021/jp800311c)
153. Wilderman, P. R., Gay, S. C., Jang, H. H., Zhang, Q., Stout, C. D. & Halpert, J. R. 2012 Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active site residues in protein-ligand interactions based on crystal structures of the ligandbound enzyme. FEBS J. 279, 1607-1620. (doi:10.1111/j.1742-4658.2011.08411.x)
154. Zhang, T., Liu, L. A., Lewis, D. F. & Wei, D. Q. 2011 Long-range effects of a peripheral mutation on the enzymatic activity of cytochrome P450 1A2. J. Chem. Inf. Model 51, 1336-1346. (doi:10.1021/ci200112b)
155. He, S. M., Zhou, Z.W., Li, X. T. & Zhou, S. F. 2011 Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr. Med. Chem. 18, 667-713. (doi:10.2174/092986711794480131)
156. Takanashi, K., Tainaka, H., Kobayashi, K., Yasumori, T., Hosakawa, M. & Chiba, K. 2000 CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10, 95-104. (doi:10.1097/00008571- 200003000-00001)
157. Sano, E., Li, W., Yuki, H., Liu, X., Furihata, T., Kobayashi, K., Chiba, K., Neya, S. & Hoshino, T. 2010 Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis. J. Comput. Chem. 31, 2746-2758. (doi:10.1002/jcc.21568)
158. Pavani, A., Naushad, S. M., Rupasree, Y., Kumar, T. R., Malempati, A. R., Pinjala, R. K., Mishra, R. C. & Kutala, V. K. 2011 Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenom. J. (doi:10.1038/tpj.2011.4)
159. Sagreiya, H., Berube, C., Wen, A., Ramakrishnan, R., Mir, A., Hamilton, A. & Altman, R. B. 2010 Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet. Genom. 20, 407-413. (doi:10.1097/FPC.0b013e328338bac2)
160. Wells, P. S., Majeed, H., Kassem, S., Langlois, N., Gin, B., Clermont, J. & Taljaard, M. 2010 A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism. Thromb. Res. 125, e259-e264. (doi:10.1016/j.thromres.2009.11.020)
161. Tan, G. M., Wu, E., Lam, Y. Y. & Yan, B. P. 2010 Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 11, 439-448. (doi:10.2217/pgs.10.8)
162. Roper, N., Storer, B., Bona, R. & Fang, M. 2010 Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn. 12, 283-291. (doi:10.2353/jmoldx. 2010.090110)
163. Schwede, T. et al. 2009 Outcome of a workshop on applications of protein models in biomedical research. Structure 17, 151-159. (doi:10.1016/j.str.2008. 12.014)
164. Tarn, C. et al. 2005 Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin. Cancer Res. 11, 3668-3677. (doi:10.1158/1078-0432.CCR-04-2515)
165. Tang, Y., Poustovoitov, M. V., Zhao, K., Garfinkel, M., Canutescu, A., Dunbrack, R., Adams, P. D. & Marmorstein, R. 2006 Structure of a human ASF1a-HIRA complex and insights into specificity of histone chaperone complex assembly. Nat. Struct. Mol. Biol. 13, 921-929. (doi:10.1038/nsmb1147)
166. Witkowski, W. A. & Hardy, J. A. 2009 L2' loop is critical for caspase-7 active site formation. Protein Sci. 18, 1459-1468. (doi:10.1002/pro.151)
167. Zhang, T., Chen, M., Lu, Y., Xing, Q. & Chen,W. 2011 A novel mutation of the PTCH1 gene activates the Shh/Gli signaling pathway in a Chinese family with nevoid basal cell carcinoma syndrome. Biochem. Biophys. Res. Commun. 409, 166-170. (doi:10.1016/j.bbrc.2011.04.047)
168. Parthiban, M., Shanmughavel, P. & Sowdhamini, R. 2010 In silico point mutation and evolutionary trace analysis applied to nicotinic acetylcholine receptors in deciphering ligand-binding surfaces. J. Mol. Model 16, 1651-1670. (doi:10.1007/s00894-010-0670-3)
169. Sabbah, D. A., Vennerstrom, J. L. & Zhong, H. 2010 Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases. J. Chem. Inf. Model 50, 1887-1898. (doi:10.1021/ci1002679)
170. Zhang, N. & Zhong, R. 2010 Structural basis for decreased affinity of Emodin binding to Val66-mutated human CK2 alpha as determined by molecular dynamics. J. Mol. Model 16, 771-780. (doi:10.1007/s00894-009-0582-2)
171. Dirauf, P., Meiselbach, H. & Sticht, H. 2010 Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease. J. Mol. Model 16, 1577-1583. (doi:10.1007/s00894-010-0677-9)
172. Gobel, U., Sander, C., Schneider, R. & Valencia, A. 1994 Correlated mutations and residue contacts in proteins. Proteins 18, 309-317. (doi:10.1002/prot.340180402)
173. Michino, M. & Brooks 3rd, C. L. 2009 Predicting structurally conserved contacts for homologous proteins using sequence conservation filters. Proteins 77, 448-453. (doi:10.1002/prot.22456)
174. Wu, S., Szilagyi, A. & Zhang, Y. 2011 Improving protein structure prediction using multiple sequence-based contact predictions. Structure 19, 1182-1191. (doi:10.1016/j.str.2011.05.004)
175. Lichtarge, O., Bourne, H. R. & Cohen, F. E. 1996 An evolutionary trace method defines binding surfaces common to protein families. J. Mol. Biol. 257, 342-358. (doi:10.1006/jmbi.1996.0167)
176. Ashkenazy, H., Erez, E., Martz, E., Pupko, T. & Ben-Tal, N. 2010 ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res. 38, W529-W533. (doi:10.1093/nar/gkq399)
177. Capra, J. A., Laskowski, R. A., Thornton, J. M., Singh, M. & Funkhouser, T. A. 2009 Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure. PLoS Comput. Biol. 5, e1000585. (doi:10.1371/journal.pcbi.1000585)
178. Vendruscolo, M. & Dobson, C. M. 2005 Towards complete descriptions of the free-energy landscapes of proteins. Phil. Trans. R. Soc. A. 363, 433-450; discussion 50-52. (doi:10.1098/rsta.2004.1501)
179. Tress, M. L. & Valencia, A. 2010 Predicted residue-residue contacts can help the scoring of 3D models. Proteins 78, 1980-1991. (doi:10.1002/prot. 22714)
180. Zhang, Y., Kolinski, A. & Skolnick, J. 2003 TOUCHSTONE II: a new approach to ab initio protein structure prediction. Biophys, J. 85, 1145-1164. (doi:10.1016/S0006-3495(03)74551-2)
181. Lindorff-Larsen, K., Best, R. B., Depristo, M. A., Dobson, C. M. & Vendruscolo, M. 2005 Simultaneous determination of protein structure and dynamics. Nature 433, 128-132. (doi:10.1038/nature03199)
182. Lange, O. F. et al. 2008 Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science 320, 1471-1475. (doi:10.1126/science.1157092)
183. de Vries, S. J., van Dijk, M. & Bonvin, A. M. 2010 The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 5, 883-897. (doi:10.1038/nprot.2010.32)
184. Bertini, I., Fragai, M., Giachetti, A., Luchinat, C., Maletta, M., Parigi, G. & Yeo, K. J. 2005 Combining in silico tools and NMR data to validate protein-ligand structural models: application to matrix metalloproteinases. J. Med. Chem. 48, 7544-7559. (doi:10.1021/jm050574k)
185. Vajda, S. & Kozakov, D. 2009 Convergence and combination of methods in protein-protein docking. Curr. Opin. Struct. Biol. 19, 164-170. (doi:10.1016/j.sbi.2009.02.008)
186. Kaufmann, K. W., Dawson, E. S., Henry, L. K., Field, J. R., Blakely, R. D. & Meiler, J. 2009 Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies. Proteins 74, 630-642. (doi:10.1002/prot.22178)
187. DeLano, W. L. 2002 The PyMOL Molecular Graphics System, version 1.2r3pre. Schrodinger, LLC.
188. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. & Ferrin, T.E. 2004 UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612. (doi:10.1002/jcc.20084)
189. Humphrey,W., Dalke, A.&Schulten,K. 1996VMD: visual molecular dynamics. J. Mol. Graph 14, 27-28, 33-38.
190. Kryshtafovych, A. & Fidelis, K. 2009 Protein structure prediction and model quality assessment. Drug Discov. Today 14, 386-393. (doi:10.1016/j. drudis.2008.11.010)
191. Pierri, C. L., Parisi, G. & Porcelli, V. 2010 Computational approaches for protein function prediction: a combined strategy from multiple sequence alignment to molecular docking-based virtual screening. Biochim. Biophys. Acta 1804, 1695-1712.
192. Zhang, Y. 2009 Protein structure prediction: when is it useful? Curr. Opin. Struct. Biol. 19, 145-155. (doi:10.1016/j.sbi.2009.02.005)
193. Kopp, J. & Schwede, T. 2004 Automated protein structure homology modeling: a progress report. Pharmacogenomics 5, 405-416. (doi:10.1517/14622416. 5.4.405)
194. Chothia, C. & Lesk, A. M. 1986 The relation between the divergence of sequence and structure in proteins. Embo J. 5, 823-826.
195. Daga, P. R., Patel, R. Y. & Doerksen, R. J. 2010 Template-based protein modeling: recent methodological advances. Curr. Top. Med. Chem. 10, 84-94. (doi:10.2174/156802610790232314)
196. Qu, X., Swanson, R., Day, R. & Tsai, J. 2009 A guide to template based structure prediction. Curr. Protein Pept. Sci. 10, 270-285. (doi:10.2174/138920309788452182)
197. Wallner, B. & Elofsson, A. 2005 All are not equal: a benchmark of different homology modeling programs. Protein Sci. 14, 1315-1327. (doi:10.1110/ps.041253405)
198. Liu, T., Tang, G. W. & Capriotti, E. 2011 Comparative modeling: the state of the art and protein drug target structure prediction. Comb. Chem. High Throughput Screen 14, 532-547. (doi:10.2174/138620711795767811)
199. Sali, A. & Blundell, T. L. 1993 Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815. (doi:10.1006/jmbi.1993.1626)
200. Levitt, M. 1992 Accurate modeling of protein conformation by automatic segment matching. J. Mol. Biol. 226, 507-533. (doi:10.1016/0022-2836(92)90964-L)
201. Larsson, P., Wallner, B., Lindahl, E. & Elofsson, A. 2008 Using multiple templates to improve quality of homology models in automated homology modeling. Protein Sci. 17, 990-1002. (doi:10.1110/ps.073344908)
202. Schwede, T., Kopp, J., Guex, N. & Peitsch, M. C. 2003 SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385. (doi:10.1093/nar/gkg520)
203. Petrey, D. et al. 2003 Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins 53 (Suppl. 6), 430-435. (doi:10.1002/prot.10550)
204. Cavasotto, C. N. & Phatak, S. S. 2009 Homology modeling in drug discovery: current trends and applications. Drug Discov. Today 14, 676-683. (doi:10.1016/j.drudis.2009.04.006)
205. Capriotti, E. & Marti-Renom, M. A. 2008 Assessment of protein structure predictions. In Computational structural biology: methods and applications (eds T. Schwede & M. C. Peitsch), pp. 89-109. Singapore, Republic of Singapore: World Scientific Publishing Company.
206. Mariani, V., Kiefer, F., Schmidt, T., Haas, J. & Schwede, T. 2011 Assessment of template based protein structure predictions in CASP9. Proteins 79 (Suppl. 10), 37-58. (doi:10.1002/prot.23177)
207. Xu, D. & Zhang, Y. 2012 Ab initio protein structure assembly using continuous structure fragments and optimized knowledge-based force field. Proteins. (doi:10.1002/prot.24065)
208. Xu, D., Zhang, J., Roy, A. & Zhang, Y. 2011 Automated protein structure modeling in CASP9 by I-TASSER pipeline combined with QUARK-based ab initio folding and FG-MD-based structure refinement. Proteins 79, 147-160. (doi:10.1002/prot.23111)
209. Kihara, D., Chen, H. & Yang, Y. D. 2009 Quality assessment of protein structure models. Curr. Protein Pept. Sci. 10, 216-228. (doi:10.2174/ 138920309788452173)
210. Simons, K. T., Kooperberg, C., Huang, E. & Baker, D. 1997 Assembly of protein tertiary structures from fragments with similar local sequences using simulated annealing and Bayesian scoring functions. J. Mol. Biol. 268, 209-225. (doi:10.1006/jmbi.1997.0959)
211. Zhang, Y. & Skolnick, J. 2004 Automated structure prediction of weakly homologous proteins on a genomic scale. Proc. Natl Acad. Sci. USA 101, 7594-7599. (doi:10.1073/pnas.0305695101)
212. Zhang, Y. 2008 Progress and challenges in protein structure prediction. Curr. Opin. Struct. Biol. 18, 342-348. (doi:10.1016/j.sbi.2008.02.004)
213. Bradley, P., Misura, K. M. & Baker, D. 2005 Toward highresolution de novo structure prediction for small proteins. Science 309, 1868-1871. (doi:10.1126/science.1113801)
214. Kryshtafovych, A., Fidelis, K. & Moult, J. 2011 CASP9 results compared to those of previous CASP experiments. Proteins 79(Suppl. 10), 196-207. (doi:10.1002/prot.23182)
215. Kinch, L., Yong Shi, S., Cong, Q., Cheng, H., Liao, Y. & Grishin, N. V. 2011 CASP9 assessment of free modeling target predictions. Proteins 79 (Suppl. 10), 59-73. (doi:10.1002/prot.23181)
216. Ghersi, D. & Sanchez, R. 2011 Beyond structural genomics: computational approaches for the identification of ligand binding sites in protein structures. J. Struct. Funct. Genom. 12, 109-117. (doi:10.1007/s10969- 011-9110-6)
217. Henrich, S., Salo-Ahen, O. M., Huang, B., Rippmann, F. F., Cruciani, G. & Wade, R. C. 2010 Computational approaches to identifying and characterizing protein binding sites for ligand design. J. Mol. Recognit. 23, 209-219.
218. Perot, S., Sperandio, O., Miteva, M. A., Camproux, A. C. & Villoutreix, B. O. 2010 Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov. Today. 15, 656-667. (doi:10.1016/j.drudis.2010.05.015)
219. Wass, M. N., Kelley, L. A. & Sternberg, M. J. 2010 3DLigandSite: predicting ligand-binding sites using similar structures. Nucleic Acids Res. 38, W469-W473. (doi:10.1093/nar/gkq406)
220. Le Guilloux, V., Schmidtke, P. & Tuffery, P. 2009 Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics 10, 168. (doi:10.1186/1471-2105-10-168)
221. Ghersi, D. & Sanchez, R. 2009 EasyMIFS and Site-Hound: a toolkit for the identification of ligand-binding sites in protein structures. Bioinformatics 25, 3185-3186. (doi:10.1093/bioinformatics/btp562)
222. Hernandez, M., Ghersi, D. & Sanchez, R. 2009 SITEHOUND-web: a server for ligand binding site identification in protein structures. Nucleic Acids Res. 37, W413-W416. (doi:10.1093/nar/gkp281)
223. Brenke, R., Kozakov, D., Chuang, G. Y., Beglov, D., Hall, D., Landon, M. R., Mattos, C. & Vajda, S. 2009 Fragment-based identification of druggable 'hot spots'of proteins using Fourier domain correlation techniques. Bioinformatics 25, 621-627. (doi:10.1093/bioinformatics/btp036)
224. Fukunishi, Y. & Nakamura, H. 2011 Prediction of ligandbinding sites of proteins by molecular docking calculation for a random ligand library. Protein Sci. 20, 95-106. (doi:10.1002/pro.540)
225. Mattos, C. & Ringe, D. 1996 Locating and characterizing binding sites on proteins. Nat. Biotechnol. 14, 595-599. (doi:10.1038/nbt0596-595)
226. Fauman, E. B., Rai, B. K. & Huang, E. S. 2011 Structurebased druggability assessment-identifying suitable targets for small molecule therapeutics. Curr. Opin. Chem. Biol. 15, 463-468. (doi:10.1016/j.cbpa.2011.05. 020)
227. Schmidtke, P., Souaille, C., Estienne, F., Baurin, N. & Kroemer, R. T. 2010 Large-scale comparison of four binding site detection algorithms. J. Chem. Inf. Model 50, 2191-2200. (doi:10.1021/ci1000289)
228. Powers, R., Copeland, J. C., Stark, J. L., Caprez, A., Guru, A. & Swanson, D. 2011 Searching the protein structure database for ligand-binding site similarities using CPASS v.2. BMC Res. Notes 4, 17. (doi:10.1186/1756-0500- 4-17)
229. Minai, R., Matsuo, Y., Onuki, H. & Hirota, H. 2008 Method for comparing the structures of protein ligandbinding sites and application for predicting protein-drug interactions. Proteins. 72, 367-381. (doi:10.1002/prot.21933)
230. Shulman-Peleg, A., Nussinov, R. & Wolfson, H. J. 2005 SiteEngines: recognition and comparison of binding sites and protein-protein interfaces. Nucleic Acids Res. 33, W337-W341. (doi:10.1093/nar/gki482)
231. Schmitt, S., Kuhn, D. & Klebe, G. 2002 A new method to detect related function among proteins independent of sequence and fold homology. J. Mol. Biol. 323, 387-406. (doi:10.1016/S0022-2836(02)00811-2)
232. Kellenberger, E., Schalon, C. & Rognan, D. 2008 How to measure the similarity between protein ligand-binding sites? Curr. Comput. Aided Drug Des. 4. (doi:10.2174/157340908785747401)
233. Liu, T. & Altman, R. B. 2011 Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding. PLoS Comput. Biol. [Research Support, N.I.H., Extramural] 7, e1002326. (doi:10.1371/journal.pcbi.1002326)
234. Corbeil, C. R., Therrien, E. & Moitessier, N. 2009 Modeling reality for optimal docking of small molecules to biological targets. Curr. Comput. Aided Drug Des. 5, 241-263. (doi:10.2174/157340909789577856)
235. Huang, S. Y., Grinter, S. Z. & Zou, X. 2010 Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. Phys. Chem. Chem. Phys. 12, 12 899-12 908. (doi:10.1039/c0cp00151a)
236. Moitessier, N., Englebienne, P., Lee, D., Lawandi, J. & Corbeil, C. R. 2008 Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br. J. Pharmacol. 153 (Suppl. 1), S7-S26. (doi:10.1038/sj.bjp.0707515)
237. Yuriev, E.,Agostino,M.&Ramsland,P. A. 2011Challenges and advances in computational docking: 2009 in review. J. Mol. Recognit. 24, 149-164. (doi:10.1002/jmr.1077)
238. Plewczynski, D., Lazniewski, M., Augustyniak, R. & Ginalski, K. 2011 Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database. J. Comput. Chem. 32, 742-755. (doi:10.1002/jcc.21643)
239. Leach, A. R., Shoichet, B. K. & Peishoff, C. E. 2006 Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J. Med. Chem. 49, 5851-5855. (doi:10.1021/jm060999m)
240. McGann, M. R., Almond, H. R., Nicholls, A., Grant, J. A. & Brown, F. K. 2003 Gaussian docking functions. Biopolymers 68, 76-90. (doi:10.1002/bip. 10207)
241. Rarey, M., Kramer, B., Lengauer, T. & Klebe, G. 1996 A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261, 470-489. (doi:10.1006/jmbi.1996.0477)
242. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K. & Olson, A. J. 1998 Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 1639-1662. (doi:10.1002/(SICI)1096-987X(19981115)19:14,1639::AID- JCC10.3.0.CO;2-B)
243. Friesner, R. A. et al. 2004 Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749. (doi:10.1021/jm0306430)
244. B-Rao, C., Subramanian, J. & Sharma, S. D. 2009 Managing protein flexibility in docking and its applications. Drug Discov. Today 14, 394-400. (doi:10.1016/j.drudis.2009.01.003)
245. Claussen, H., Buning, C., Rarey, M. & Lengauer, T. 2001 FlexE: efficient molecular docking considering protein structure variations. J. Mol. Biol. 308, 377-395. (doi:10.1006/jmbi.2001.4551)
246. Mizutani, M. Y., Takamatsu, Y., Ichinose, T., Nakamura, K. & Itai, A. 2006 Effective handling of induced-fit motion in flexible docking. Proteins 63, 878-891. (doi:10.1002/prot.20931)
247. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. & Olson, A. J. 2009 Auto-Dock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791. (doi:10.1002/jcc.21256)
248. Feher, M. & Williams, C. I. 2009 Effect of input differences on the results of docking calculations. J. Chem. Inf. Model 49, 1704-1714. (doi:10.1021/ci9000629)
249. Corbeil, C. R. & Moitessier, N. 2009 Docking ligands into flexible and solvated macromolecules. 3. Impact of input ligand conformation, protein flexibility, and water molecules on the accuracy of docking programs. J. Chem. Inf. Model 49, 997-1009. (doi:10.1021/ci8004176)
250. Kolb, P., Ferreira, R. S., Irwin, J. J. & Shoichet, B. K. 2009 Docking and chemoinformatic screens for new ligands and targets. Curr. Opin. Biotechnol. 20, 429-436. (doi:10.1016/j.copbio.2009.08.003)
251. Ballester, P. J. & Mitchell, J. B. 2010 A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking. Bioinformatics 26, 1169-1175. (doi:10.1093/bioinformatics/btq112)
252. Deng, W., Breneman, C. & Embrechts, M. J. 2004 Predicting protein-ligand binding affinities using novel geometrical descriptors and machine-learning methods. J. Chem. Inf. Comput. Sci. 44, 699-703. (doi:10.1021/ci034246+)
253. Adcock, S. A. & McCammon, J. A. 2006 Molecular dynamics: survey of methods for simulating the activity of proteins. Chem. Rev. 106, 1589-1615. (doi:10.1021/cr040426m)
254. Lee, E. H., Hsin, J., Sotomayor, M., Comellas, G. & Schulten, K. 2009 Discovery through the computational microscope. Structure 17, 1295-1306. (doi:10.1016/j.str.2009.09.001)
255. Schlick, T., Collepardo-Guevara, R., Halvorsen, L. A., Jung, S. & Xiao, X. 2011 Biomolecularmodeling and simulation: a field coming of age. Q. Rev. Biophys. 44, 191-228. (doi:10.1017/S0033583510000284)
256. Fan, H., Irwin, J. J., Webb, B. M., Klebe, G., Shoichet, B. K. & Sali, A. 2009 Molecular docking screens using comparative models of proteins. J. Chem. Inf. Model 49, 2512-2527. (doi:10.1021/ci9003706)
257. Ivetac, A. & McCammon, J. A. 2010 Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. Chem. Biol. Drug Des. 76, 201-217.
258. Salsbury Jr., F. R. 2010 Molecular dynamics simulations of protein dynamics and their relevance to drug discovery. Curr. Opin. Pharmacol. 10, 738-744. (doi:10.1016/j.coph.2010.09.016)
259. Shan, Y., Kim, E. T., Eastwood, M. P., Dror, R. O., Seeliger, M. A. & Shaw, D. E. 2011 How does a drug molecule find its target binding site? J. Am. Chem. Soc. 133, 9181-9183. (doi:10.1021/ja202726y)
260. Rajasekaran, R. & Sethumadhavan, R. 2010 Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach. AminoAcids39, 651-660. (doi:10.1007/s00726-010-0486-6)
261. Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. O., Dror, R. O., Kuriyan, J. & Shaw, D. E. 2009 A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc. Natl Acad. Sci. USA 106, 139-144. (doi:10.1073/pnas.0811223106)
262. Jorgensen, W. L., Maxwell, D. S. & Tirado-Rives, J. 1996 Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118, 11 225-11 236. (doi:10.1021/ja9621760)
263. MacKerell, A. D. J. et al. 1998 All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586-3616. (doi:10.1021/jp973084f)
264. Cornell, W. D. et al. 1995 A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117, 5179-5197. (doi:10.1021/ja00124a002)
265. Freddolino, P. L., Park, S., Roux, B. & Schulten, K. 2009 Force field bias in protein folding simulations. Biophys. J. 96, 3772-3780. (doi:10.1016/j.bpj.2009.02.033)
266. Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E. & Berendsen, H. J. 2005 GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701-1718. (doi:10.1002/jcc.20291)
267. Pearlman, D. A., Case, D. A., Caldwell, J. W., Ross, W. S., Cheatham III, T. E., DeBolt, S., Ferguson, D., Seibel, G. & Kollman, P. 1995 AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 91, 1-41. (doi:10.1016/0010-4655(95)00041-D)
268. Kalé, L. et al. 1999 NAMD2: greater scalability for parallel molecular dynamics. J. Comput. Phys. 151, 283-312. (doi:10.1006/jcph.1999.6201)
269. Friedrichs, M. S., Eastman, P., Vaidyanathan, V., Houston, M., Legrand, S., Beberg, A. L., Ensign, D. L., Bruns, C. M. & Pande, V. S. 2009 Accelerating molecular dynamic simulation on graphics processing units. J. Comput. Chem. 30, 864-872. (doi:10.1002/jcc.21209)
270. Pande, V. S. et al. 2003 Atomistic protein folding simulations on the submillisecond timescale using worldwide distributed computing. Biopolymers 68, 91-109. (doi:10.1002/bip.10219)
271. Shaw, D. E. et al. 2010 Atomic-level characterization of the structural dynamics of proteins. Science 330, 341-346. (doi:10.1126/science.1187409)
272. Mobley, D. L. 2012 Let's get honest about sampling. J. Comput. Aided Mol. Des. 26, 93-95. (doi:10.1007/s10822-011-9497-y)
273. Bray, J. K., Weiss, D. R. & Levitt, M. 2011 Optimized torsion-angle normal modes reproduce conformational changes more accurately than cartesian modes. Biophys. J. 101, 2966-2969. (doi:10.1016/j.bpj.2011.10.054)
274. Yang, L., Song, G. & Jernigan, R. L. 2007 How well can we understand large-scale protein motions using normal modes of elastic network models? Biophys. J. 93, 920-929. (doi:10.1529/biophysj.106.095927)
275. Hinsen, K. 1998 Analysis of domain motions by approximate normal mode calculations. Proteins 33, 417-429. (doi:10.1002/(SICI)1097-0134(19981115)33:3, 417::AID-PROT10.3.0.CO;2-8)
276. Suhre, K. & Sanejouand, Y. H. 2004 ElNemo, a normal mode web server for protein movement analysis and the generation of templates for molecular replacement. Nucleic Acids Res. 32, W610-W614. (doi:10.1093/nar/gkh368)
277. Bahar, I., Lezon, T. R., Bakan, A. & Shrivastava, I. H. 2010 Normal mode analysis of biomolecular structures, functional mechanisms of membrane proteins. Chem. Rev. 110, 1463-1497. (doi:10.1021/cr900095e)
278. Torrance, J. W., Bartlett, G. J., Porter, C. T. & Thornton, J. M. 2005 Using a library of structural templates to recognise catalytic sites and explore their evolution in homologous families. J. Mol. Biol. 347, 565-581. (doi:10.1016/j.jmb.2005.01.044)
279. Lopez, G., Valencia, A. & Tress, M. 2007 FireDB-a database of functionally important residues from proteins of known structure. Nucleic Acids Res. 35, D219-D223. (doi:10.1093/nar/gkl897)
280. Pieper, U. et al. 2011 ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res. 39, D465-D474. (doi:10.1093/nar/gkq1091)
281. Arnold, K., Kiefer, F., Kopp, J., Battey, J. N., Podvinec, M., Westbrook, J. D., Nerman, H. M., Bordoli, L. & Schwede, T. 2009 The protein model portal. J. Struct. Funct. Genom. 10, 1-8. (doi:10.1007/s10969-008-9048-5)
282. Kellenberger, E., Muller, P., Schalon, C., Bret, G., Foata, N. & Rognan, D. 2006 sc-PDB: an annotated database of druggable binding sites from the Protein Data Bank. J. Chem. Inf. Model 46, 717-727. (doi:10.1021/ci050372x)
283. Gold, N. D. & Jackson, R. M. 2006 SitesBase: a database for structure-based protein-ligand binding site comparisons. Nucleic Acids Res. 34, D231-D234. (doi:10.1093/nar/gkj062)
284. Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L. & Schwede, T. 2009 The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 37, D387-D392. (doi:10.1093/nar/gkn750)
285. Hu, L., Benson, M. L., Smith, R. D., Lerner, M. G. & Carlson, H. A. 2005 Binding MOAD (Mother Of All Databases). Proteins 60, 333-340. (doi:10.1002/prot.20512)
286. Wang, R., Fang, X., Lu, Y. & Wang, S. 2004 The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J. Med. Chem. 47, 2977-2980. (doi:10.1021/ jm030580l)
287. Hendlich, M., Bergner, A., Gunther, J. & Klebe, G. 2003 Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. J. Mol. Biol. 326, 607-620. (doi:10.1016/S0022- 2836(02)01408-0)
288. Gabanyi, M. J. 2011 The structural biology knowledgebase: a portal to protein structures, sequences, functions, and methods. J. Struct. Funct. Genom. 12, 45-54. (doi:10.1007/s10969-011-9106-2)
289. Zhu, F. et al. 2010 Update of TTD: therapeutic target database. Nucleic Acids Res. 38, D787-D791. (doi:10.1093/nar/gkp1014)
290. Sherry, S. T., Ward, M. H., Kholodov, M., Baker, J., Phan, L., Smigielski, E. M. & Sirotkin, K. 2001 dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311. (doi:10.1093/nar/29.1.308)
291. Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S. & Manolio, T. A. 2009 Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106, 9362-9367. (doi:10.1073/pnas.0903103106)
292. Amberger, J., Bocchini, C. & Hamosh, A. 2011 A new face and new challenges for Online Mendelian Inheritance in Man (OMIM(R)). Hum. Mutat. 32, 564-567. (doi:10.1002/humu.21466)
293. Gamazon, E. R., Zhang, W., Konkashbaev, A., Duan, S., Kistner, E. O., Nicolae, D. L., Dolan, M. E. & Cox, N. J. 2010 SCAN: SNP and copy number annotation. Bioinformatics 26, 259-262. (doi:10.1093/bioinformatics/btp644)
294. Mottaz, A., David, F. P., Veuthey, A. L. & Yip, Y. L. 2010 Easy retrieval of single amino-acid polymorphisms and phenotype information using SwissVar. Bioinformatics 26, 851-852. (doi:10.1093/bioinformatics/btq028)
295. Ryan, M., Diekhans, M., Lien, S., Liu, Y. & Karchin, R. 2009 LS-SNP/PDB: annotated non-synonymous SNPs mapped to Protein Data Bank structures. Bioinformatics 25, 1431-1432. (doi:10.1093/bioinformatics/btp242)
296. Yang, J. O., Oh, S., Ko, G., Park, S. J., Kim, W. Y., Lee, B. & Lee, S. 2011 VnD: a structure-centric database of disease-related SNPs and drugs. Nucleic Acids Res. 39, D939-D944. (doi:10.1093/nar/gkq957)
297. Preissner, S. et al. 2010 SuperCYP: a comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 38, D237-D243. (doi:10.1093/nar/gkp970)
298. Thorn, C. F., Klein, T. E. & Altman, R. B. 2010 Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 11, 501-505. (doi:10.2217/pgs.10.15)
299. Meslamani, J., Rognan, D. & Kellenberger, E. 2011 sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins. Bioinformatics 27, 1324-1326. (doi:10.1093/bioinformatics/btr120)
300. Aller, S. G. et al. 2009 Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722. (doi:10.1126/science.1168750)
301. Warne, T., Moukhametzianov, R., Baker, J. G., Nehme, R., Edwards, P. C., Leslie, A. G., Schertler, G. F. & Tate, C. G. 2011 The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature 469, 241-244. (doi:10.1038/nature09746)
302. Rasmussen, S. G. et al. 2007 Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450, 383-387. (doi:10.1038/ nature06325)
303. Rutherford, K., Le Trong, I., Stenkamp, R. E. & Parson, W. W. 2008 Crystal structures of human 108V and 108M catechol O-methyltransferase. J. Mol. Biol. 380, 120-130. (doi:10.1016/j.jmb.2008.04.040)
304. Yano, J. K., Hsu, M. H., Griffin, K. J., Stout, C. D. & Johnson, E. F. 2005 Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol. 12, 822-823. (doi:10.1038/nsmb971)
305. Gay, S. C. et al. 2010 Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution. Mol. Pharmacol. 77, 529-538. (doi:10.1124/mol.109.062570)
306. Rowland, P. et al. 2006 Crystal structure of human cytochrome P450 2D6. J. Biol. Chem. 281, 7614-7622. (doi:10.1074/jbc.M511232200)
307. Dobritzsch, D., Ricagno, S., Schneider, G., Schnackerz, K. D. & Lindqvist, Y. 2002 Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer. J. Biol. Chem. 277, 13 155-13 166.
308. Tellez-Sanz, R. et al. 2006 Calorimetric and structural studies of the nitric oxide carrier S-nitrosoglutathione bound to human glutathione transferase P1-1. Protein Sci. 15, 1093-1105. (doi:10.1110/ps.052055206)
309. Wu, H. et al. 2007 Structural basis of allele variation of human thiopurine-S-methyltransferase. Proteins 67, 198-208. (doi:10.1002/prot.21272)
310. Faratian, D., Bown, J. L., Smith, V. A., Langdon, S. P. & Harrison, D. J. 2010 Cancer systems biology. Meth. Mol. Biol. 662, 245-263. (doi:10.1007/978-1-60761-800-3-12)
311. Prasasya, R. D.,Vang, K. Z.&Kreeger, P. K. 2011Amultivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib. Biotechnol. Bioeng. 109, 213-224. (doi:10.1002/bit.23297)
312. Yang, R., Niepel, M., Mitchison, T. K. & Sorger, P. K. 2010 Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin. Pharmacol. Ther. 88, 34-38. (doi:10.1038/clpt.2010.96)
313. Barabasi, A. L., Gulbahce, N. & Loscalzo, J. 2011 Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68. (doi:10.1038/nrg2918)
314. RCSB PDB Statistics [database on the Internet]. 2011 RCSB Protein Data Bank. [cited August 6, 2011]. Available from: http://www.pdb.org/pdb/static.do? p=general-information/pdb-statistics/index.html.
315. Wang, W. et al. 2006 Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl Acad. Sci. USA 103, 3563-3568. (doi:10.1073/pnas.0600048103)
316. Standfuss, J., Edwards, P. C., D'Antona, A., Fransen, M., Xie, G., Oprian, D. D. & Schertler, G. F. X. 2011 The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471, 656-660. (doi:10.1038/nature09795)
317. Nielsen, R., Paul, J. S., Albrechtsen, A. & Song, Y. S. 2011 Genotype and SNP calling from next-generation sequencing data. Nat. Rev. Genet. 12, 443-451. (doi:10.1038/nrg2986)
318. Zhang, C. C. & Kast, J. 2010 Applications of current proteomics techniques in modern drug design. Curr. Comput. Aided Drug Des. 6, 147-164. (doi:10.2174/157340910791760064)
319. Mandal, S., Moudgil, M. & Mandal, S. K. 2009 Rational drug design. Eur. J. Pharmacol. 625, 90-100. (doi:10.1016/j.ejphar.2009.06.065)
320. Talele,T.T., Khedkar, S.A.&Rigby, A.C. 2010 Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr. Top. Med. Chem. 10, 127-241. (doi:10.2174/156802610790232251)
321. Villoutreix, B. O., Eudes, R. & Miteva, M. A. 2009 Structure- based virtual ligand screening: recent success stories. Comb. Chem. High Throughput Screen 12, 1000-1016. (doi:10.2174/138620709789824682)
322. Andricopulo, A. D., Salum, L. B. & Abraham, D. J. 2009 Structure-based drug design strategies in medicinal chemistry. Curr. Top. Med. Chem. 9, 771-790. (doi:10.2174/156802609789207127)
323. Kalyaanamoorthy, S. & Chen, Y. P. 2011 Structure-based drug design to augment hit discovery. Drug Discov. Today 16, 831-839. (doi:10.1016/j.drudis. 2011.07.006)
324. Hubbard, R. E. 2011 Structure-based drug discovery and protein targets in the CNS. Neuropharmacology 60, 7-23. (doi:10.1016/j.neuropharm.2010.07.016)
325. Cozier, G. E., Leese, M. P., Lloyd, M. D., Baker, M. D., Thiyagarajan, N., Acharya, K. R. & Potter, K. V. 2010 Structures of human carbonic anhydrase II/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors. Biochemistry 49, 3464-3476. (doi:10.1021/bi902178w)
326. Blackburn, E. A. & Walkinshaw, M. D. 2011 Targeting FKBP isoforms with small-molecule ligands. Curr. Opin. Pharmacol. 11, 365-371. (doi:10.1016/j.coph.2011.04.007)
327. Crespan, E., Zucca, E. & Maga, G. 2011 Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models. Curr. Med. Chem. 18, 2836-2847. (doi:10.2174/ 092986711796150513)
328. Moriaud, F., Richard, S. B., Adcock, S. A., Chanas-Martin, L., Surgand, J. S., Ben Jelloul, M. & Delfaud, F. 2011 Identify drug repurposing candidates by mining the protein data bank. Brief Bioinform. 12, 336-340. (doi:10.1093/bib/bbr017)
329. Ekins, S., Williams, A. J., Krasowski, M. D. & Freundlich, J. S. 2011 In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov. Today 16, 298-310. (doi:10.1016/j.drudis.2011.02.016)
330. Haupt, V. J. & Schroeder, M. 2011 Old friends in new guise: repositioning of known drugs with structural bioinformatics. Brief Bioinform. 12, 312-326. (doi:10.1093/bib/bbr011)
331. Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B. & Sorger, P. K. 2006 Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466. (doi:10.1038/nchembio817)
332. Zhang, J. et al. 2010 Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506. (doi:10.1038/nature08675)